Several NAFLD-related factors are considered to contribute to CVD risk including dysregulation of lipoprotein metabolism leading to atherogenic dyslipidaemia [41], as low HDLc and higher apoB/apoA-I ratio [42,43]; altered glucose metabolism [44,45]; altered gut microbiome [46]; and chronic inflammation [47]. This evidence concerns the gene APOA1 and metabolic dysfunction-associated steatotic liver disease.